HBQ1
gene geneOn this page
Also known as HBQ
Summary
HBQ1 (hemoglobin subunit theta 1, HGNC:4833) is a protein-coding gene on chromosome 16p13.3, encoding Hemoglobin subunit theta-1 (P09105).
Theta-globin mRNA is found in human fetal erythroid tissue but not in adult erythroid or other nonerythroid tissue. The theta-1 gene may be expressed very early in embryonic life, perhaps sometime before 5 weeks. Theta-1 is a member of the human alpha-globin gene cluster that involves five functional genes and two pseudogenes. The order of genes is: 5’ - zeta - pseudozeta - mu - pseudoalpha-2 -pseudoalpha-1 - alpha-2 - alpha-1 - theta-1 - 3’. Research supports a transcriptionally active role for the gene and a functional role for the peptide in specific cells, possibly those of early erythroid tissue.
Source: NCBI Gene 3049 — RefSeq curated summary.
At a glance
- GWAS associations: 19
- Clinical variants (ClinVar): 27 total — 1 pathogenic
- MANE Select transcript:
NM_005331
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4833 |
| Approved symbol | HBQ1 |
| Name | hemoglobin subunit theta 1 |
| Location | 16p13.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | HBQ |
| Ensembl gene | ENSG00000086506 |
| Ensembl biotype | protein_coding |
| OMIM | 142240 |
| Entrez | 3049 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000199708
RefSeq mRNA: 1 — MANE Select: NM_005331
NM_005331
CCDS: CCDS10400
Canonical transcript exons
ENST00000199708 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000663730 | 180980 | 181179 |
| ENSE00001118463 | 180459 | 180581 |
| ENSE00001769246 | 180666 | 180870 |
Expression profiles
Bgee: expression breadth ubiquitous, 141 present calls, max score 90.49.
FANTOM5 (CAGE): breadth broad, TPM avg 2.7202 / max 168.6941, expressed in 354 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 151870 | 2.7202 | 354 |
Top tissues by expression
280 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| blood | UBERON:0000178 | 90.49 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 85.57 | gold quality |
| monocyte | CL:0000576 | 84.54 | gold quality |
| mononuclear cell | CL:0000842 | 84.35 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 83.21 | gold quality |
| leukocyte | CL:0000738 | 82.90 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 82.27 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 76.92 | gold quality |
| cingulate cortex | UBERON:0003027 | 76.80 | gold quality |
| nucleus accumbens | UBERON:0001882 | 75.55 | gold quality |
| bone marrow | UBERON:0002371 | 74.91 | gold quality |
| amygdala | UBERON:0001876 | 74.86 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 73.48 | gold quality |
| right frontal lobe | UBERON:0002810 | 72.59 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 72.46 | gold quality |
| granulocyte | CL:0000094 | 72.24 | gold quality |
| caudate nucleus | UBERON:0001873 | 70.53 | gold quality |
| putamen | UBERON:0001874 | 67.40 | gold quality |
| cortical plate | UBERON:0005343 | 65.51 | gold quality |
| hypothalamus | UBERON:0001898 | 65.01 | gold quality |
| bone marrow cell | CL:0002092 | 64.49 | gold quality |
| telencephalon | UBERON:0001893 | 64.36 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 63.69 | gold quality |
| forebrain | UBERON:0001890 | 62.92 | gold quality |
| cerebral cortex | UBERON:0000956 | 62.83 | gold quality |
| temporal lobe | UBERON:0001871 | 62.68 | gold quality |
| neocortex | UBERON:0001950 | 62.04 | gold quality |
| Ammon’s horn | UBERON:0001954 | 61.47 | gold quality |
| vena cava | UBERON:0004087 | 61.45 | gold quality |
| brain | UBERON:0000955 | 60.99 | gold quality |
Single-cell (SCXA)
Detected in 11 experiment(s), a significant marker in 11.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-98 | yes | 144.62 |
| E-HCAD-4 | yes | 142.80 |
| E-CURD-112 | yes | 51.46 |
| E-MTAB-10042 | yes | 44.71 |
| E-MTAB-9221 | yes | 17.99 |
| E-HCAD-9 | yes | 10.79 |
| E-MTAB-9388 | yes | 9.44 |
| E-MTAB-9067 | yes | 7.23 |
| E-ANND-3 | yes | 7.14 |
| E-HCAD-10 | yes | 6.81 |
| E-MTAB-9467 | yes | 3.88 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 1)
- 2 new Spanish alpha-thalassemia mutations were found. In both mutations, both alpha genes were deleted, the gene theta; and the region HS40. (PMID:21453942)
Cross-species orthologs
8 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Hbq1a | ENSMUSG00000020295 |
| mus_musculus | Hbq1b | ENSMUSG00000073063 |
| rattus_norvegicus | ENSRNOG00000070249 | |
| rattus_norvegicus | ENSRNOG00000074159 | |
| rattus_norvegicus | ENSRNOG00000087981 | |
| drosophila_melanogaster | glob1 | FBGN0027657 |
| caenorhabditis_elegans | WBGENE00008996 | |
| caenorhabditis_elegans | WBGENE00077763 |
Paralogs (11): HBZ (ENSG00000130656), CYGB (ENSG00000161544), HBA2 (ENSG00000188536), HBG2 (ENSG00000196565), MB (ENSG00000198125), HBA1 (ENSG00000206172), HBM (ENSG00000206177), HBE1 (ENSG00000213931), HBG1 (ENSG00000213934), HBD (ENSG00000223609), HBB (ENSG00000244734)
Protein
Protein identifiers
Hemoglobin subunit theta-1 — P09105 (reviewed: P09105)
Alternative names: Hemoglobin theta-1 chain, Theta-1-globin
All UniProt accessions (2): P09105, A0A1K0GUV5
UniProt curated annotations — full annotation on UniProt →
Similarity. Belongs to the globin family.
RefSeq proteins (1): NP_005322* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000971 | Globin | Domain |
| IPR002338 | Hemoglobin_a-typ | Family |
| IPR002339 | Hemoglobin_pi | Family |
| IPR009050 | Globin-like_sf | Homologous_superfamily |
| IPR012292 | Globin/Proto | Homologous_superfamily |
| IPR050056 | Hemoglobin_oxygen_transport | Family |
Pfam: PF00042
UniProt features (4 total): binding site 2, chain 1, domain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P09105-F1 | 96.59 | 0.97 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (2): 59 (distal binding residue); 88 (proximal binding residue)
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 72 (showing top):
GOBP_MYELOID_CELL_DIFFERENTIATION, GNF2_PRDX2, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_ERYTHROCYTE_HOMEOSTASIS, GNF2_ANK1, GOBP_GAS_TRANSPORT, GOBP_OXYGEN_TRANSPORT, GNF2_SPTA1, GNF2_PCAF, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, GOMF_OXYGEN_BINDING, GOBP_ERYTHROCYTE_DEVELOPMENT, GNF2_MAP2K3, GOBP_HOMEOSTATIC_PROCESS
GO Biological Process (2): oxygen transport (GO:0015671), erythrocyte development (GO:0048821)
GO Molecular Function (6): oxygen carrier activity (GO:0005344), iron ion binding (GO:0005506), oxygen binding (GO:0019825), heme binding (GO:0020037), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (2): hemoglobin complex (GO:0005833), haptoglobin-hemoglobin complex (GO:0031838)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| protein-containing complex | 2 |
| gas transport | 1 |
| erythrocyte differentiation | 1 |
| myeloid cell development | 1 |
| oxygen transport | 1 |
| oxygen binding | 1 |
| molecular carrier activity | 1 |
| transition metal ion binding | 1 |
| small molecule binding | 1 |
| tetrapyrrole binding | 1 |
| binding | 1 |
| cation binding | 1 |
| cytosol | 1 |
Protein interactions and networks
STRING
530 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| HBQ1 | LUC7L | Q9NQ29 | 856 |
| HBQ1 | NPRL3 | Q12980 | 546 |
| HBQ1 | HBE1 | P02100 | 502 |
| HBQ1 | HPRT1 | P00492 | 497 |
| HBQ1 | AHSP | Q9NZD4 | 473 |
| HBQ1 | HBD | P02042 | 465 |
| HBQ1 | EPB42 | P16452 | 453 |
| HBQ1 | ALAS2 | P22557 | 451 |
| HBQ1 | UTY | O14607 | 442 |
| HBQ1 | STEAP4 | Q687X5 | 438 |
| HBQ1 | FAM234A | Q9H0X4 | 432 |
| HBQ1 | HBB | P02023 | 431 |
| HBQ1 | HBZ | P02008 | 428 |
| HBQ1 | GUF1 | Q8N442 | 423 |
| HBQ1 | FECH | P22830 | 416 |
IntAct
44 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| HBQ1 | RFESD | psi-mi:“MI:0915”(physical association) | 0.780 |
| HBD | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.720 |
| HBQ1 | HBD | psi-mi:“MI:0915”(physical association) | 0.720 |
| AHCYL1 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.600 |
| HBQ1 | HBA1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBQ1 | NTAQ1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBQ1 | HBG2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBZ | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBQ1 | HBB | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBE1 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| NIF3L1 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HBQ1 | IGLL5 | psi-mi:“MI:0914”(association) | 0.350 |
| HBQ1 | FASN | psi-mi:“MI:0914”(association) | 0.350 |
| CDKN2D | HBQ1 | psi-mi:“MI:0914”(association) | 0.350 |
| RFESD | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| AHCYL1 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| HBQ1 | HBA1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| NTAQ1 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| HBG2 | HBQ1 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (34): HBQ1 (Two-hybrid), RFESD (Two-hybrid), HBZ (Two-hybrid), WDYHV1 (Two-hybrid), AHCYL1 (Two-hybrid), RFESD (Two-hybrid), HBA2 (Two-hybrid), HBG2 (Two-hybrid), HBA1 (Two-hybrid), HBE1 (Two-hybrid), HBD (Two-hybrid), HBB (Two-hybrid), ZG16B (Affinity Capture-MS), PIGR (Affinity Capture-MS), FASN (Affinity Capture-MS)
ESM2 similar proteins: A1A4Q3, B0M2T2, O12985, P01998, P02000, P02005, P02006, P02112, P02113, P02115, P02116, P02117, P02118, P02120, P02121, P02122, P02123, P02124, P02126, P06714, P06890, P07036, P07406, P07411, P08851, P09105, P0C0U7, P10058, P10062, P10781, P11896, P14261, P14523, P14524, P21668, P22742, P30893, P68061, P68062, P68063
Diamond homologs: B3EWE3, D0VX09, P01923, P01924, P01926, P01928, P01929, P01930, P01934, P01935, P01937, P01938, P01939, P01940, P01941, P01948, P01951, P01953, P01956, P01958, P01959, P01960, P01961, P01962, P01963, P01964, P01965, P01966, P01967, P01971, P01973, P04237, P06635, P06714, P06890, P07402, P07405, P07421, P07425, P08258
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 13 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| oxygen transport | 6 | 526.6× | 6e-15 |
| erythrocyte development | 6 | 263.3× | 5e-13 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
27 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 22 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 144341 | GRCh38/hg38 16p13.3(chr16:180542-181197)x1 | Pathogenic |
SpliceAI
178 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 16:180578:A:T | donor_gain | 1.0000 |
| 16:180578:AAAGG:A | donor_loss | 0.9900 |
| 16:180581:GGT:G | donor_loss | 0.9900 |
| 16:180583:T:A | donor_loss | 0.9900 |
| 16:180660:TCGCA:T | acceptor_loss | 0.9900 |
| 16:180662:GCAG:G | acceptor_loss | 0.9900 |
| 16:180663:CA:C | acceptor_loss | 0.9900 |
| 16:180664:A:AG | acceptor_gain | 0.9900 |
| 16:180665:G:GG | acceptor_gain | 0.9900 |
| 16:180867:CCAGG:C | donor_loss | 0.9900 |
| 16:180868:CAGGT:C | donor_loss | 0.9900 |
| 16:180870:GGT:G | donor_loss | 0.9900 |
| 16:180871:G:GA | donor_loss | 0.9900 |
| 16:180872:T:G | donor_loss | 0.9900 |
| 16:180664:AG:A | acceptor_gain | 0.9800 |
| 16:180665:GG:G | acceptor_gain | 0.9800 |
| 16:180665:GGACC:G | acceptor_gain | 0.9800 |
| 16:180665:GGA:G | acceptor_gain | 0.9700 |
| 16:180665:GGAC:G | acceptor_gain | 0.9700 |
| 16:180710:T:TA | acceptor_gain | 0.9500 |
| 16:180577:G:GT | donor_gain | 0.9300 |
| 16:180591:GC:G | donor_gain | 0.9000 |
| 16:180661:C:CA | acceptor_gain | 0.8900 |
| 16:180871:G:GG | donor_gain | 0.8800 |
| 16:180999:T:A | acceptor_gain | 0.8600 |
| 16:180978:A:AG | acceptor_gain | 0.8500 |
| 16:180979:G:GG | acceptor_gain | 0.8500 |
| 16:180582:G:GG | donor_gain | 0.8400 |
| 16:181024:C:CA | acceptor_gain | 0.8300 |
| 16:181026:G:C | acceptor_gain | 0.8200 |
AlphaMissense
895 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 16:180679:T:C | F37L | 0.923 |
| 16:180681:C:A | F37L | 0.923 |
| 16:180681:C:G | F37L | 0.923 |
| 16:180700:T:C | F44L | 0.920 |
| 16:180702:C:A | F44L | 0.920 |
| 16:180702:C:G | F44L | 0.920 |
| 16:181064:T:C | F129L | 0.901 |
| 16:181066:C:A | F129L | 0.901 |
| 16:181066:C:G | F129L | 0.901 |
| 16:180865:T:C | F99L | 0.881 |
| 16:180867:C:A | F99L | 0.881 |
| 16:180867:C:G | F99L | 0.881 |
| 16:180529:T:A | W15R | 0.861 |
| 16:180529:T:C | W15R | 0.861 |
| 16:180994:C:G | C105W | 0.853 |
| 16:180571:G:C | A29P | 0.839 |
| 16:180749:G:A | G60D | 0.837 |
| 16:180666:G:C | R32S | 0.834 |
| 16:180666:G:T | R32S | 0.834 |
| 16:181065:T:C | F129S | 0.829 |
| 16:180701:T:C | F44S | 0.822 |
| 16:180572:C:A | A29D | 0.821 |
| 16:180760:G:C | A64P | 0.817 |
| 16:181077:T:A | V133D | 0.806 |
| 16:180766:G:C | A66P | 0.804 |
| 16:180563:C:A | T26K | 0.797 |
| 16:180531:G:C | W15C | 0.795 |
| 16:180531:G:T | W15C | 0.795 |
| 16:180992:T:C | C105R | 0.790 |
| 16:180761:C:A | A64E | 0.785 |
dbSNP variants (sampled 300 via entrez): RS1000984958 (16:181378 A>G), RS1002414361 (16:178924 CA>C,CAA), RS1002672675 (16:179716 A>G), RS1002747324 (16:178719 G>A,C), RS1002823969 (16:181088 C>G), RS1003158228 (16:180073 G>A,T), RS1004026578 (16:180466 G>A,C), RS1004241607 (16:180261 C>T), RS1004343642 (16:180879 C>G,T), RS1004356061 (16:180694 A>G), RS1004908099 (16:179598 T>A), RS1005364 (16:180482 C>A,G,T), RS1005436369 (16:179310 G>A), RS1006866651 (16:179404 A>C), RS1007202789 (16:179177 C>T)
Disease associations
OMIM: gene MIM:142240 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
19 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST003122_1 | Hemoglobin levels | 6.000000e-18 |
| GCST004601_134 | Red blood cell count | 7.000000e-31 |
| GCST004602_220 | Mean corpuscular volume | 1.000000e-85 |
| GCST004605_10 | Mean corpuscular hemoglobin concentration | 3.000000e-52 |
| GCST004619_59 | Reticulocyte fraction of red cells | 4.000000e-11 |
| GCST004630_168 | Mean corpuscular hemoglobin | 2.000000e-12 |
| GCST004630_169 | Mean corpuscular hemoglobin | 1.000000e-109 |
| GCST010083_266 | Hemoglobin levels | 2.000000e-16 |
| GCST90002384_354 | Hemoglobin | 1.000000e-24 |
| GCST90002386_276 | High light scatter reticulocyte percentage of red cells | 1.000000e-27 |
| GCST90002390_630 | Mean corpuscular hemoglobin | 2.000000e-214 |
| GCST90002391_159 | Mean corpuscular hemoglobin concentration | 3.000000e-09 |
| GCST90002391_160 | Mean corpuscular hemoglobin concentration | 4.000000e-90 |
| GCST90002392_476 | Mean corpuscular volume | 3.000000e-179 |
| GCST90002396_645 | Mean reticulocyte volume | 4.000000e-12 |
| GCST90002397_273 | Mean spheric corpuscular volume | 5.000000e-37 |
| GCST90002403_657 | Red blood cell count | 4.000000e-119 |
| GCST90002404_332 | Red cell distribution width | 1.000000e-32 |
| GCST90002406_402 | Reticulocyte fraction of red cells | 2.000000e-49 |
EFO canonical traits (8, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004509 | hemoglobin measurement |
| EFO:0007629 | hemoglobin A1 measurement |
| EFO:0004305 | erythrocyte count |
| EFO:0004528 | mean corpuscular hemoglobin concentration |
| EFO:0007986 | reticulocyte count |
| EFO:0004527 | mean corpuscular hemoglobin |
| EFO:0010701 | mean reticulocyte volume |
| EFO:0009188 | Red cell distribution width |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
24 total (human), top 24 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, increases expression, increases methylation | 3 |
| propionaldehyde | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| butyraldehyde | increases expression | 1 |
| perfluorooctanoic acid | increases expression | 1 |
| perfluorobutyric acid | increases expression | 1 |
| pentanal | increases expression | 1 |
| tebuconazole | decreases expression | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Aldehydes | increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cisplatin | affects cotreatment, increases expression | 1 |
| Diethylhexyl Phthalate | decreases expression | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Rotenone | increases expression | 1 |
| Tunicamycin | decreases expression | 1 |
| Urethane | decreases expression | 1 |
| 1-Methyl-4-phenylpyridinium | increases expression | 1 |
| Sodium Selenite | decreases expression | 1 |
| Thapsigargin | decreases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.